An interventional study of Blood analysis, spectral CT scan and cardiac magnetic resonance imaging (CMR) study and Blood analysis and spectral CT study in Acute Myocardial Infarction (AMI), sponsored by Instituto de Investigación Biomédica de Salamanca. Recruiting at 4 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Instituto de Investigación Biomédica de Salamanca · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Myocardial Infarction with a site in Spain — 19 open to participants now, 27 under way, 7 of them phase 3. Myocardial Infarction · Spain.
Among the 131 studies in Myocardial Infarction with a site in Spain, this one is the 84th largest by planned enrollment of the 98 interventional ones that give a count, is one of 4 that started in 2025, is one of 29 with no phase, reaches primary completion later than 11 of the 26 other live ones, and was the 124th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →19 of the 131 studies in Myocardial Infarction with a site in Spain are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Spain, Ireland, Latvia and 2 more countries
Ages 18+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 65+
Sergio Mies Padilla · Sites in Spain
Ages 18+
Novo Nordisk A/S · Sites in Spain, Austria, Denmark and 3 more countries
Ages 18+
Abcentra · Sites in Spain, United States, Czechia and 6 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 35 · Phase 4 16
First in 2002; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 95 is below the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 445 across the 98 interventional studies, 1,498 across the 33 observational. Of the 91 that completed or were terminated, 29 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 131 have an industry lead sponsor. The 10 most frequent:
Instituto de Investigación Biomédica de Salamanca is the lead sponsor of 20 studies on the registry; 15 are open to participants now.
Instituto de Investigación Biomédica de Salamanca has 1 study filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
8 of the studies in Myocardial Infarction with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT06799780IRCCS Azienda Ospedaliero-Universitaria di BolognaStudy on Post-acute Myocardial Infarction Ventricular Defect: Outcome Evalutation in Relation to Surgical Timing | 2026-11-30 |
| NCT04973397Centre hospitalier de l'Université de Montréal (CHUM)Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study | 2026-12 |
| NCT07268391Instituto de Investigación Biomédica de SalamancaUsing Advanced CT Scans and Blood Markers to Better Understand Heart Damage and Recovery After a Heart Attack | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 131 studies in Myocardial Infarction with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Acute myocardial infarction with ST-segment elevation (STEMI) remains a leading cause of morbidity and mortality worldwide. Although advances in reperfusion therapy have reduced early mortality, many patients later develop adverse ventricular remodeling (AVR), which increases the risk of heart failure and cardiovascular death. Current imaging methods, such as echocardiography and cardiac magnetic resonance (CMR), provide valuable prognostic information but have limitations in availability, cost, and their ability to predict AVR early and individually.
Spectral computed tomography (CT) is an emerging imaging technique that can characterize myocardial tissue, quantify infarct size, assess microvascular obstruction, and detect complications, with lower contrast and radiation requirements compared to conventional CT. In parallel, circulating microRNAs (miRNAs) have been identified as stable and non-invasive biomarkers that reflect key biological processes in post-infarction remodeling. Several miRNAs are linked to fibrosis, apoptosis, and ventricular remodeling, suggesting their potential to complement imaging findings in risk prediction.
This study proposes a multicenter, prospective cohort of patients with STEMI and reduced left ventricular function to evaluate whether combining spectral CT tissue characterization with serum miRNA profiling can improve early prediction of AVR. The main objective is to generate and validate a multiparametric prognostic model integrating imaging and molecular biomarkers to identify high-risk patients who may benefit from closer monitoring and tailored therapeutic strategies.
Background and Rationale Acute myocardial infarction with ST-segment elevation (STEMI) continues to represent a major public health challenge, being one of the leading causes of morbidity and mortality worldwide. Advances in reperfusion therapy, particularly primary percutaneous coronary intervention (PCI), have substantially reduced short-term mortality rates. Nevertheless, a large proportion of patients experience adverse ventricular remodeling (AVR) during follow-up. AVR is characterized by pathological changes in left ventricular (LV) geometry, wall thinning, chamber dilation, and progressive decline in contractile function. These changes are strongly associated with the development of heart failure and increased long-term mortality.
Traditional imaging modalities, such as echocardiography and cardiac magnetic resonance (CMR), have been used to characterize post-infarction myocardial damage and to monitor remodeling. Echocardiography is widely available and provides important functional information, but it lacks the ability to characterize myocardial tissue in depth. CMR is currently the gold standard for infarct size quantification, detection of microvascular obstruction, and assessment of myocardial viability; however, it is costly, time-consuming, and not universally accessible. There remains an unmet need for more accessible, rapid, and accurate tools to predict AVR early after STEMI.
Spectral computed tomography (CT) has recently emerged as an innovative imaging technique that goes beyond conventional CT by providing spectral information and material decomposition. This technology enables enhanced tissue characterization, accurate quantification of myocardial perfusion defects, and identification of complications such as myocardial rupture or thrombus, all while using reduced contrast volume and lower radiation doses compared with older-generation scanners. Preliminary data suggest that spectral CT can approximate some of the information traditionally obtained through CMR, potentially offering a more accessible tool for post-infarction risk stratification.
In parallel, circulating microRNAs (miRNAs) have been identified as highly stable, non-invasive biomarkers involved in key biological processes relevant to cardiac remodeling, including fibrosis, apoptosis, angiogenesis, and inflammatory signaling. Several miRNAs have been associated with infarct size, LV dysfunction, and clinical outcomes in patients with acute myocardial infarction. Integrating molecular biomarkers with imaging could provide a powerful multiparametric model for early prediction of AVR, guiding patient-tailored therapeutic strategies.
The SPECTRAMI-CARE study (SPEctral CT and miRna In Acute Myocardial Infarction for Comprehensive Adverse Remodeling Evaluation) is designed as a prospective, multicenter observational cohort. The protocol aims to evaluate the complementary role of spectral CT and circulating miRNAs in predicting adverse remodeling after STEMI with impaired LV function.
Imaging Procedures
Spectral CT:
Performed within the first week after STEMI. Parameters include assessment of infarct size, perfusion defects, myocardial edema, and complications (e.g., thrombus, aneurysm). Quantitative indices will be derived from material decomposition images, iodine density maps, and virtual monoenergetic reconstructions.
Cardiac MRI (sub-cohort):
Used as a reference standard for infarct size, microvascular obstruction, and myocardial viability. Data will be compared with spectral CT findings for concordance and accuracy.
Echocardiography:
Performed at baseline and follow-up for routine functional assessment (LV volumes, LVEF, diastolic function, right ventricular parameters).
Molecular Biomarker Assessment Peripheral blood samples will be collected at baseline (≤72h after PCI), at 1 month, and at 3 months. miRNA profiling will be performed using next-generation sequencing and validated with quantitative RT-PCR. Candidate miRNAs previously implicated in fibrosis, apoptosis, angiogenesis, and remodeling will be specifically analyzed. Expression levels will be correlated with imaging findings and clinical outcomes.
Statistical Analysis Sample size will be based on expected incidence of AVR (\~30% in high-risk STEMI populations). Multivariable logistic regression and Cox proportional hazards models will be used to identify predictors of AVR and clinical outcomes. Model performance will be evaluated using C-statistics, calibration plots, and net reclassification improvement (NRI). Internal validation will be performed with bootstrapping; external validation will be explored in an independent cohort.
Ethics and Dissemination The study will comply with the Declaration of Helsinki and local ethics regulations. Informed consent will be obtained from all participants. Data will be anonymized and stored securely. Results will be disseminated through peer-reviewed publications and presentations at scientific conferences, with the aim of contributing to precision medicine in post-infarction care.
Significance SPECTRAMI-CARE is expected to provide novel insights into the early identification of patients at risk for adverse remodeling after STEMI. By integrating cutting-edge imaging and molecular biomarkers, this study seeks to advance risk stratification and facilitate personalized strategies to improve outcomes. Spectral CT, if validated against CMR, may offer a more accessible alternative for myocardial tissue characterization, while circulating miRNAs may add a non-invasive layer of biological information. The multiparametric model proposed has the potential to change clinical practice by identifying high-risk patients earlier and enabling targeted therapeutic interventions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At the coordinating center (CAUSA), a control group (n = 20) will be included, consisting of patients with a clinical indication for cardiac CT for reasons other than myocardial infarction, meeting the following criteria: absence of myocardial injury or structural heart disease, ≤1 cardiovascular risk factor, LVEF \> 55%, and no significant valvular disease (grade \< III).
Procedure: Blood analysis and spectral CT study
Patientes will be included in this group if the following requirements are met: Hospital admission due to STEMI, treated in accordance with current clinical practice guidelines. Left ventricular systolic dysfunction, defined as a left ventricular ejection fraction (LVEF) \< 50%, assessed by transthoracic echocardiography (TTE) within the first 24-72 hours of admission. Provision of signed informed consent.
Procedure: Blood analysis, spectral CT scan and cardiac magnetic resonance imaging (CMR) study
After providing informed consent, patients will undergo blood sampling, a spectral CT scan scheduled between the 3rd and 7th day of hospitalization (acute phase), and a cardiac magnetic resonance imaging (CMR) study performed within a maximum of 72 hours from the CT.
Patients who meet the inclusion criteria for the control group will be invited to participate in the study. They will undergo blood sampling and the planned spectral CT study, including a late iodine enhancement acquisition.
Incidence of adverse ventricular remodeling at 6 months, defined as an increase in LV end-diastolic volume ≥20% compared with baseline.
The primary endpoint will be the occurrence of adverse ventricular remodeling (AVR) as assessed by cardiac magnetic resonance imaging (CMR). AVR will be defined as an increase in left ventricular end-diastolic volume (LVEDV) of ≥20% compared with baseline values obtained during the acute phase (3-7 days post-STEMI). In cases where CMR is not feasible, spectral CT-derived LV volumes will be used as a contingency reference, given their validated correlation with CMR measurements.
Time frame: 6 months
Infarct size characterization by spectral CT vs. CMR.
Quantitative assessment of infarct size will be performed using spectral CT (late iodine enhancement, iodine concentration maps, and non-contrast acquisitions for edema) and compared with CMR (late gadolinium enhancement, T1/T2 mapping, and extracellular volume fraction).
Time frame: Baseline and 6 months
Myocardial characterization by spectral CT vs. CMR.
Quantitative assessment of myocardial markers such as microvascular obstruction (MVO), intramyocardial hemorrhage, and myocardial edema will be evaluated to determine the diagnostic accuracy and reproducibility of spectral CT (late iodine enhancement, iodine concentration maps, and non-contrast acquisitions for edema) and compared with the gold standard CMR (late gadolinium enhancement, T1/T2 mapping, and extracellular volume fraction).
Time frame: Baseline and 6 months
Correlation of miRNA signatures with remodeling.
Serum miRNA profiles obtained at baseline (acute phase) and at 6 months will be analyzed to identify differential expression patterns associated with adverse remodeling. Specific miRNAs previously linked to fibrosis, apoptosis, and inflammation (e.g., miR-1, miR-21, miR-30a-5p, miR-133a, miR-210-3p, miR-221-3p) will be quantified by RT-qPCR. Qualitative correlation between miRNA expression levels and imaging-defined markers of remodeling will be tested, including potential sex-specific differences.
Time frame: Baseline and 6 months
Predictive accuracy of integrated models (spectral CT + miRNA vs. conventional predictors)
Predictive models will be developed combining spectral CT-derived parameters, miRNA signatures, and conventional clinical predictors (age, sex, infarct location, Killip class, biomarkers). Model performance will be assessed using machine learning approaches (logistic regression, random forest, XGBoost), with internal validation through repeated 10-fold cross-validation. Predictive accuracy will be reported using receiver-operating characteristic (ROC) curves, area under the curve (AUC), calibration statistics, and Shapley values for interpretability. All parameters sill be used simultaneously to predict integrated models, therefore they cannot be sepparated in different outcomes.
Time frame: 6 months
Major adverse cardiovascular events (MACE)
The composite endpoint of MACE will include cardiovascular death, recurrent myocardial infarction, and hospitalization for heart failure during the 12-month follow-up period. All events will be adjudicated by an independent clinical events committee, blinded to imaging and biomarker results.
Time frame: From baseline to 6 months
Safety outcomes: incidence of contrast-induced nephropathy
Safety outcomes will be carefully annotated, including incidence of contrast-induced nephropathy (defined as a ≥30% decline in estimated glomerular filtration rate compared with baseline).
Time frame: From baseline to 6 months
Safety outcomes: allergic or hypersensitivity reactions
Aallergic or hypersensitivity reactions to iodinated contrast or gadolinium-based agents will be assessed.
Time frame: From baseline to 6 months
Safety outcomes: arrhythmias related to imaging procedures
Arrhythmias temporally related to imaging procedures (e.g., during CT or CMR acquisition) will be evaluated.
Time frame: From baseline to 6 months
Safety outcomes: Cumulative radiation exposure
Cumulative radiation exposure from spectral CT will also be recorded and reported as an additional safety metric.
Time frame: From baseline to 6 months
Plan to share: Yes — Plan Description: De-identified individual participant-level data (IPD) will be shared, including: Demographic and clinical variables collected in REDCap. Quantitative spectral CT parameters (iodine maps, first-pass perfusion, late iodine enhancement, volumetric data). Cardiac MRI parameters (volumes, T1/T2 mapping, ECV, MVO, IMH). Serum miRNA panel results (derived files and processed tables). Clinical outcomes (adverse ventricular remodeling defined by indexed EDV/ESV, 1-year MACE, renal function, etc.). Supporting documents (data dictionary, eCRFs, analysis scripts in R/Python when available, FAIR metadata) will also be provided.
Supporting information: Study protocol, Informed consent form, Clinical study report
Time frame: Beginning 12 months after publication of primary results, available for at least 5 years.
Access criteria: Access Criteria: Access will be granted to qualified researchers with a methodologically sound proposal. Requests will be reviewed by the study Data Committee/steering committee. Applications must be addressed to the PI (Candelas Pérez del Villar). Requirements include: Data Use Agreement (DUA), commitment to non-reidentification, appropriate data security, mandatory citation of dataset source and DOI. Analytical code sharing and a publication plan may be required prior to access approval. IPD Sharing Support: Data will be hosted on controlled project infrastructure (XNAT/Core-lab) and disseminated through the IBSAL Zenodo community with DOI and regulated access, in compliance with GDPR/LOPDGDD and CEIm approval.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.
Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 16 months is below that.
Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto de Investigación Biomédica de Salamanca